Hevascol

Hevascol is a pharmaceutical product whose active ingredient is ethyl esters of iodised fatty acids derived from poppyseed oil. It is supplied without a listed strength and is intended for intra‑arterial or intralymphatic administration. Marketed in the European Union, Hevascol belongs to a class of lipid‑based agents used in specialized vascular or lymphatic procedures. Its composition reflects a purified esterified fatty‑acid mixture for clinical use.

Hevascol is employed in specific medical settings where intra‑arterial or intralymphatic delivery of lipid‑based agents is required.

- Vascular imaging procedures to enhance arterial visualization. - Lymphatic mapping during oncologic surgery. - Adjunct in selective arterial embolization. - Experimental studies of fatty‑acid metabolism in localized tissues. - Supportive role in certain interventional radiology protocols.

Adverse reactions to Hevascol may vary in frequency and severity.

Common: - Mild injection site discomfort or erythema. - Transient headache. - Nausea or mild gastrointestinal upset. - Temporary flushing or warmth sensation. - Minor changes in blood pressure that resolve spontaneously.

Serious: - Allergic hypersensitivity reactions, including rash or angioedema. - Severe vasospasm at the injection site. - Acute renal impairment in susceptible individuals. - Pulmonary embolism if inadvertently introduced into the venous system. - Significant hemorrhage related to vascular injury.

When considering Hevascol, clinicians should evaluate patient-specific factors and procedural context.

- Verify absence of known iodine or poppyseed oil allergy before administration. - Assess renal function, as iodinated agents may affect kidney performance. - Use caution in patients with coagulation disorders or on anticoagulant therapy. - Monitor vital signs during and after intra‑arterial or intralymphatic injection. - Ensure proper catheter placement to avoid extravasation. - Document any prior adverse reactions to similar lipid‑based contrast agents. - Consider alternative imaging methods for pregnant or lactating individuals.

Hevascol may interact with other substances administered during interventional procedures.

Avoid: - Concurrent use of high‑dose iodinated contrast agents, which can increase iodine load. - Administration of potent vasoconstrictors that may exacerbate vascular spasm. - Co‑administration with nephrotoxic drugs in patients with compromised renal function.

Use with caution: - Anticoagulants or antiplatelet agents, due to potential bleeding risk at the injection site. - Beta‑blockers, as they may influence hemodynamic responses. - Diuretics, which could affect fluid balance and contrast distribution. - Sedatives or analgesics that mask early signs of adverse reactions.